Cns pharmaceuticals, inc.CNSP.US Overview
CNSP Overall Performance
CNSP AI Analysis & Strategy
CNSP Recent Performance
3.96%
Cns pharmaceuticals, inc.
1.30%
Avg of Sector
0.61%
S&P500
CNSP PowerScanner
CNSP Key Information
CNSP Valuation Metrics
CNSP Earnings Table
CNSP Profile
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.